Biomea Fusion Inc. has announced its 2026 strategy focused on advancing its investigational metabolic programs. The company plans to move icovamenib, a covalent menin inhibitor, into late-stage clinical development with two Phase II trials targeting insulin-deficient type 2 diabetes and type 2 diabetes patients inadequately controlled on GLP-1-based therapies. Enrollment for both studies is expected to begin in the first quarter of 2026, with primary endpoint results anticipated in the fourth quarter. Additionally, Biomea will continue clinical development of BMF-650, an oral next-generation GLP-1 receptor agonist for obesity and metabolic disorders. Initial 28-day weight loss clinical data from the Phase I study of BMF-650 in obese, otherwise healthy volunteers is expected in the second quarter of 2026. The company aims to deliver durable clinical benefits by advancing medicines designed to modify the underlying biology of diabetes and obesity.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623710-en) on January 12, 2026, and is solely responsible for the information contained therein.
